Table 3.

Univariate analysis of metastatic sites as predictors of MYCN status in patients with stage 4 neuroblastoma.¹

Metastatic site1	Sample size (N)2	Percent with metastatic site (%)	MYCN-Non amplified (%)3	MYCN-amplified (%)3	P-value4	Odds Ratio5
Bone marrow	2171				0.002	1.4
Yes		72.1	68.1	31.9
No		27.9	74.9	25.1
Bone	2164				0.006	1.3
Yes		58.8	67.9	32.2
No		41.2	73.3	26.7
Distant lymph node	2165				0.76	1.0
Yes		33.9	70.4	29.6
No		66.1	69.8	30.2
Liver	2172				0.74	1.0
Yes		18.1	69.4	30.6
No		81.9	70.2	29.8
Skin	1958				0.01	0.4
Yes		3.3	84.6	15.4
No		96.7	70.1	29.9
Lung	1923				<0.001	3.0
Yes		4.1	46.2	53.9
No		95.9	71.7	28.3
Central Nervous System	1923				0.6	1.2
Yes		2.6	67.4	32.7
No		97.4	70.8	29.2
Other	2128				<0.001	1.5
Yes		27.8	64.2	35.8
No		72.2	72.5	27.5

¹At least one known metastatic site specified in the INRG database.

²N represents total with known data for the given variable.

³Row percentages sum to 100%.

⁴p-value refers to a chi-squared test.

⁵Odds ratio for univariate logistic regression with MYCN amplification as dependent variable.